How do I install the Endo Ace Arb Ccb Htn skill?

Run npx skillmds@latest add dromlakhani/endo-ace-arb-ccb-htn in your terminal (requires Node.js), paste this page's agent-chat prompt into Claude, Cursor, or any MCP-connected agent, or download the SKILL.md file and copy it into your agent's skills directory.

Is Endo Ace Arb Ccb Htn safe to use?

SkillMD's automated safety review verdict for this skill is PASS. Independent scanners report: SkillSpector: PASS, Skill Scanner: PASS. Capability flags: docs only. SkillMD never runs a skill's scripts for you; review the SKILL.md before installing.

Which AI agents work with Endo Ace Arb Ccb Htn?

This skill is tagged as working with Claude Code, Claude.ai, OpenAI Codex. SKILL.md is an open format, so most agents that read a skills directory can load it too.

Is Endo Ace Arb Ccb Htn free to use?

Yes. Installing skills from SkillMD is free, and the skill stays under its author's original license.

Who published Endo Ace Arb Ccb Htn?

dromlakhani (@dromlakhani) published this skill. Their other Agent Skills are listed on their SkillMD profile.

Endo Ace Arb Ccb Htn by dromlakhani

Name: Endo Ace Arb Ccb Htn
Rating: 4.2 (5 reviews)
Author: dromlakhani

Endo Ace Arb Ccb Htn

Recommends ACE inhibitors, ARBs, or calcium channel blockers as first-line hypertension therapy rather than β‑adrenergic blockers in obese patients with type 2 diabetes. Triggers include when a clinician asks, 'What antihypertensive should I start for this obese patient with T2DM to avoid weight gain?' or 'Should I avoid β‑blockers in this patient with diabetes and hypertension?'

dromlakhani Updated Aug 19, 2026 10 repo stars

File contents

Prefer ACE/ARB/CCB over β‑blockers for hypertension in T2DM obese

STEP 1 — Gather Information

Confirm diagnosis of type 2 diabetes, obesity (BMI ≥ 30 kg/m² or BMI ≥ 27 kg/m² with comorbidity), and presence of hypertension; assess for contraindications to ACEI/ARB/CCB (pregnancy, bilateral renal artery stenosis, hyperkalemia, angioedema history) and for compelling β‑blocker indications (HFrEF, post‑MI, angina).

STEP 2 — Rule In / Rule Out

If a compelling β‑blocker indication exists (e.g., HFrEF, recent MI), consider β‑blocker; otherwise, rule out β‑blocker as first‑line and proceed to ACE/ARB/CCB selection.

STEP 3 — Classify or Stratify

Choose agent based on comorbidities: ACEI or ARB preferred if albuminuria, CKD, or heart failure with preserved EF; CCB preferred if edema risk is low and patient needs avoidance of cough/hyperkalemia; avoid ACEI/ARB in pregnancy or bilateral stenosis.

STEP 4 — Decide

Initiate the selected ACEI, ARB, or CCB at low dose, titrate to target BP; document avoidance of β‑blocker unless a compelling indication arises later.

Clinical Guardrails / Mimics / Pitfalls

Do not use β‑blockers solely for hypertension in obese T2DM due to risk of weight gain, worsened insulin resistance, and masking hypoglycemia symptoms; avoid non‑selective β‑blockers without vasodilating properties; do not combine ACEI and ARB; monitor for ACEI‑related cough or angioedema, ARB‑related hyperkalemia, and CCB‑related peripheral edema.

Concrete Clinical Example

A 58‑year‑old woman with T2DM, BMI 34 kg/m², BP 152/96 mmHg, no heart failure or post‑MI, is started on lisinopril 10 mg daily after confirming no contraindications; β‑blocker is avoided to limit weight gain and insulin resistance.

Source: Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2015, DOI:10.1210/jc.2014-3415

---name: endo-ace-arb-ccb-htndescription: Recommends ACE inhibitors, ARBs, or calcium channel blockers as first-line hypertension therapy rather than β‑adrenergic blockers in obese patients with type 2 diabetes. Triggers include when a clinician asks, 'What antihypertensive should I start for this obese patient with T2DM to avoid weight gain?' or 'Should I avoid β‑blockers in this patient with diabetes and hypertension?'---# Prefer ACE/ARB/CCB over β‑blockers for hypertension in T2DM obese## STEP 1 — Gather InformationConfirm diagnosis of type 2 diabetes, obesity (BMI ≥ 30 kg/m² or BMI ≥ 27 kg/m² with comorbidity), and presence of hypertension; assess for contraindications to ACEI/ARB/CCB (pregnancy, bilateral renal artery stenosis, hyperkalemia, angioedema history) and for compelling β‑blocker indications (HFrEF, post‑MI, angina).## STEP 2 — Rule In / Rule OutIf a compelling β‑blocker indication exists (e.g., HFrEF, recent MI), consider β‑blocker; otherwise, rule out β‑blocker as first‑line and proceed to ACE/ARB/CCB selection.## STEP 3 — Classify or StratifyChoose agent based on comorbidities: ACEI or ARB preferred if albuminuria, CKD, or heart failure with preserved EF; CCB preferred if edema risk is low and patient needs avoidance of cough/hyperkalemia; avoid ACEI/ARB in pregnancy or bilateral stenosis.## STEP 4 — DecideInitiate the selected ACEI, ARB, or CCB at low dose, titrate to target BP; document avoidance of β‑blocker unless a compelling indication arises later.## Clinical Guardrails / Mimics / PitfallsDo not use β‑blockers solely for hypertension in obese T2DM due to risk of weight gain, worsened insulin resistance, and masking hypoglycemia symptoms; avoid non‑selective β‑blockers without vasodilating properties; do not combine ACEI and ARB; monitor for ACEI‑related cough or angioedema, ARB‑related hyperkalemia, and CCB‑related peripheral edema.## Concrete Clinical ExampleA 58‑year‑old woman with T2DM, BMI 34 kg/m², BP 152/96 mmHg, no heart failure or post‑MI, is started on lisinopril 10 mg daily after confirming no contraindications; β‑blocker is avoided to limit weight gain and insulin resistance.**Source:** Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2015, DOI:10.1210/jc.2014-3415

Frequently asked questions